The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...
Visceral fat vs subcutaneous fat are the key differences, health risks, and why visceral fat is considered more dangerous.
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...
Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), ...
It Takes a Village! Navigating the Challenges and Opportunities in Immune-Related Adverse Event Management More broadly than this study, several contextual factors need to be considered before simply ...
FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...
A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...
Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...
Argenx’s subcutaneous formulation of the active ingredient in Vyvgart has hit the primary endpoint in a phase 3 trial, clearing the biotech to file for approval of a product it expects to become the ...
MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...
The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).
3d
TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program
Power reported total global revenue for 2025 of $616 million, with $594 million in U.S. BRIUMVI net product revenue and $12.8 million in sales to Neuraxpharm. Quarterly net income was $23 million, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results